Mycobacterium abscessus and β-Lactams: Emerging Insights and Potential Opportunities

Frontiers in Microbiology

Elizabeth Story-Roller¹  Gyanu Lamichhane¹  Emily C. Maggioncalda¹  Keira A. Cohen² 

[1] Division of Infectious Diseases, School of Medicine, Johns Hopkins University, Baltimore, MD, United States;Division of Pulmonary and Critical Care Medicine, School of Medicine, Johns Hopkins University, Baltimore, MD, United States;

关键词: Mycobacterium abscessus;    β-lactams;    peptidoglycan;    LD-transpeptidase;    β-lactamase inhibitor;   

DOI  :  10.3389/fmicb.2018.02273

来源: DOAJ

【 摘 要 】

β-lactams, the most widely used class of antibiotics, are well-tolerated, and their molecular mechanisms of action against many bacteria are well-documented. Mycobacterium abscessus (Mab) is a highly drug-resistant rapidly-growing nontuberculous mycobacteria (NTM). Only in recent years have we started to gain insight into the unique relationship between β-lactams and their targets in Mab. In this mini-review, we summarize recent findings that have begun to unravel the molecular basis for overall efficacy of β-lactams against Mab and discuss emerging evidence that indicates that we have yet to harness the full potential of this antibiotic class to treat Mab infections.

【 授权许可】

Unknown